What Is Wegener’s Disease? Symptoms, Diagnosis & Treatment

Wegener’s disease, now officially called granulomatosis with polyangiitis (GPA), is a rare autoimmune condition in which the immune system attacks the walls of small and medium-sized blood vessels, causing widespread inflammation and tissue damage. The disease primarily targets the respiratory tract and kidneys, though it can reach nearly every organ system. GPA belongs to a family of conditions known as ANCA-associated vasculitis, named for the antibodies that drive the disease and serve as one of its key diagnostic markers.

Why the Name Changed

For decades, this disease was known simply as Wegener’s granulomatosis, after Friedrich Wegener, a German pathologist. The formal description under that name dates to a 1954 article in the Archives of Pathology & Laboratory Medicine by Godman and Churg, which linked various forms of what we now recognize as small-vessel vasculitis.¹ In 2011, rheumatology and nephrology societies officially replaced the eponym with “granulomatosis with polyangiitis” for two reasons. First, concerns emerged about Wegener’s wartime associations. Second, the new name actually describes the disease: “granulomatosis” refers to the characteristic clumps of inflamed tissue (granulomas) found in biopsies, and “polyangiitis” means inflammation across many blood vessels.² You will still see “Wegener’s” in older textbooks and patient forums, and many doctors use the abbreviation GPA interchangeably with the older name.

What Causes the Disease

The exact cause remains unknown, but the central players are anti-neutrophil cytoplasmic antibodies, or ANCA. In most people with GPA, the immune system produces antibodies that target a protein called proteinase 3 (PR3) found on the surface of neutrophils, a type of white blood cell. When these antibodies bind to neutrophils, they trigger the cells to activate inappropriately. The activated neutrophils release toxic substances directly into the walls of blood vessels, and this sets off a chain reaction that includes activation of part of the complement system, creating an intense inflammatory environment that damages tissue.³

Why certain people develop these rogue antibodies in the first place is less clear. Researchers believe that infections, environmental exposures, and genetic predisposition all contribute. Several susceptibility genes have been identified through genome-wide studies, including genes involved in immune regulation such as CTLA4 and PTPN22, as well as a cluster of immune-system genes in the HLA region.⁴ None of these genes alone is enough to cause the disease, and GPA does not follow a simple inherited pattern. Having a first-degree relative with it raises your risk slightly, but the vast majority of cases appear in people with no family history.

Symptoms and the Organs Involved

GPA is sometimes described as a disease with two faces: a “limited” form that stays mainly in the upper airways, and a “generalized” or “severe” form that spreads to the lungs, kidneys, and beyond. Many patients start with the limited form and progress if untreated, though the timeline varies enormously from person to person.

Upper Airway and Ear, Nose, and Throat Symptoms

About 70% of patients first show up with ear, nose, or throat complaints, making this the single most common way GPA announces itself.⁵ Persistent nasal congestion that does not respond to typical allergy or cold treatments is a hallmark. Patients often develop crusting inside the nose, recurrent nosebleeds, and sometimes a perforated nasal septum. Over time, destruction of cartilage can produce a “saddle nose” deformity where the bridge of the nose collapses inward. Chronic sinusitis that resists antibiotics is another red flag.

One of the more dangerous upper-airway complications is subglottic stenosis, a narrowing of the airway just below the vocal cords. This can cause progressive shortness of breath, a hoarse voice, or stridor (a high-pitched sound when breathing in). In severe cases patients require tracheostomy to maintain a safe airway.⁶ Subglottic stenosis can also persist or recur even after the systemic disease is brought under control, making it one of the trickier long-term management problems.

Lung Involvement

When GPA reaches the lungs, it tends to produce nodules, areas of ground-glass haziness on imaging, or both. Lung nodules are typically multiple and bilateral, usually ranging from about 2 to 4 cm in diameter, though they can grow much larger. Roughly a quarter of nodules bigger than 2 cm develop cavities, which can look like lung abscesses or even cancer on a CT scan.⁷ This overlap with cancer imaging is one reason GPA is sometimes caught only after a biopsy intended to rule out malignancy.

The most life-threatening lung complication is diffuse alveolar hemorrhage, in which inflamed capillaries in the lung tissue bleed into the air sacs. Estimates of how often this occurs in GPA patients range widely, from roughly 7% to 45%.⁷ When it happens, the patient may cough up blood, develop rapidly worsening shortness of breath, and show new widespread shadows on a chest CT. This is a medical emergency requiring intensive care and aggressive immunosuppressive treatment.⁸

Kidney Disease

Renal involvement is one of the defining features of generalized GPA and a major driver of both short-term danger and long-term complications. The typical pattern is a rapidly progressive inflammation of the glomeruli, the kidney’s tiny filtering units. This can cause blood and protein to appear in the urine, rising creatinine levels, and, if left unchecked, kidney failure. In one study tracking GPA patients over time, about 7% progressed to end-stage kidney disease, and all of those cases occurred within the first three years after diagnosis.⁹

Eye Problems

GPA affects the eyes in roughly half of all patients, and the range of possible problems is wide. Inflammation can target the orbit (the bony socket around the eye), the sclera (the white of the eye), the conjunctiva, or deeper structures like the retina and optic nerve. In one cohort, orbital masses were the most common eye-related finding, followed by surface inflammation of the conjunctiva and sclera.¹⁰ About 5% of patients in that study suffered permanent vision loss, underscoring the importance of routine eye exams in anyone with GPA.¹⁰

Systemic Symptoms

Beyond these organ-specific problems, most patients experience constitutional symptoms like fatigue, joint pain, weight loss, and fevers, especially during active flares. These nonspecific complaints are part of what makes early GPA so easy to mistake for a lingering infection or another autoimmune condition.

How GPA Is Diagnosed

There is no single test that definitively confirms GPA. Diagnosis relies on a combination of clinical features, blood tests, imaging, and, ideally, tissue biopsy. ANCA blood testing plays a central role: the antibodies targeting PR3 (called c-ANCA or anti-PR3) are the most characteristic marker. A meta-analysis of ANCA testing methods found that modern immunoassay screening for anti-PR3 antibodies achieves a sensitivity between roughly 80% and 87%, with specificity in the range of 97% to 98%.¹¹ In practical terms, a positive anti-PR3 result in someone with the right symptoms is strong evidence for GPA, while a negative result does not rule it out entirely.

A 2017 international consensus shifted the recommended first-line screening from an older microscopy-based method to direct immunoassay testing for PR3 and MPO antibodies. Real-world validation of that approach at a large hospital in the Netherlands showed that starting with immunoassay alone yielded 100% sensitivity and about 99% specificity in their cohort.¹²

Even with good blood tests, biopsy remains important. ANCA testing is not a substitute for examining tissue under a microscope, especially in ambiguous cases.¹³ When biopsies are taken from the nose, sinuses, or lungs, the classic findings include granulomas, areas of tissue death (necrosis), and small-vessel inflammation. In practice, though, not every biopsy shows the full triad. In one review of non-kidney biopsies from GPA patients, granulomas appeared in only about 43% of samples, characteristic necrosis in 35%, and small-vessel vasculitis in 23%.¹⁴ A biopsy that shows one or two of these features in the right clinical context still supports the diagnosis, but the incomplete picture is why GPA can be slow to confirm.

Conditions That Mimic GPA

The overlap between GPA and other diseases creates real diagnostic pitfalls. One that trips up clinicians is cocaine-induced midline destructive lesion. Heavy cocaine use, particularly snorting, can destroy nasal tissue and cartilage in a pattern that looks almost identical to GPA. To make matters more confusing, cocaine users can test positive for ANCA antibodies, making serologic testing unreliable in that context.¹⁵ Given how common cocaine use is, clinicians need to ask about drug history before attributing nasal destruction to vasculitis, because the treatments are completely different and immunosuppressive drugs given for a misdiagnosis carry serious risks.

Other conditions in the differential include the other ANCA-associated vasculitides (microscopic polyangiitis and eosinophilic granulomatosis with polyangiitis), infections like tuberculosis, sarcoidosis, and lymphoma. Imaging alone cannot sort these apart when lung nodules are the primary finding, which is part of why biopsy and careful clinical evaluation remain so important.

Treatment of Active Disease

Treatment for GPA is divided into two phases: induction, where the goal is to shut down active inflammation and achieve remission, and maintenance, where the goal is to keep the disease quiet and prevent relapses.

Induction Therapy

For decades, the standard induction regimen was high-dose corticosteroids combined with cyclophosphamide, a potent immunosuppressive drug originally developed as a chemotherapy agent. This combination is effective but comes with serious side effects, including increased infection risk, bladder toxicity, and long-term cancer risk. Over the past fifteen years, rituximab, an antibody that depletes a specific subset of immune cells called B cells, has emerged as an alternative. A weighted analysis comparing the two in GPA patients found that about 73% of those receiving rituximab reached the primary outcome versus roughly 40% on cyclophosphamide.¹⁶ Rituximab has become the preferred first-line induction agent at many centers, though cyclophosphamide remains an important option for certain patients, particularly those with very severe kidney involvement.

Maintenance Therapy

Once remission is achieved, the disease needs to be kept in check, because GPA has a strong tendency to relapse. Historically, azathioprine or methotrexate served as maintenance drugs. Rituximab, given at lower and less frequent doses than during induction, has shown clear superiority over azathioprine for preventing relapses. One international randomized trial reported that rituximab reduced the risk of relapse by about 59% compared with azathioprine.¹⁷ A separate study found that roughly 19% of patients on rituximab maintenance relapsed within 18 months, compared with about 67% of those on azathioprine, and none of the rituximab-group relapses were classified as major.¹⁸

Reducing Steroid Dependence

Corticosteroids remain part of nearly every induction regimen, but their long-term side effects, including bone thinning, diabetes, weight gain, and increased infection risk, make doctors eager to taper them as quickly as possible. A newer drug called avacopan, which blocks a receptor involved in complement-driven inflammation (the C5a receptor), has shown promise as a steroid-sparing agent. Case reports describe patients whose steroid doses were significantly reduced after adding avacopan to their regimen, with rapid improvement in symptoms.¹⁹ Avacopan received regulatory approval for GPA and the related condition microscopic polyangiitis, representing the first truly new mechanism of action for these diseases in years.

Plasma Exchange and When It Might Help

Plasma exchange, a procedure that filters the blood to physically remove ANCA antibodies and inflammatory proteins, has had a complicated history in GPA management. An earlier trial (the MEPEX trial) involving patients with very severe kidney disease found that 69% of those who received plasma exchange were alive and off dialysis at three months, compared with 49% in the control group.²⁰ That benefit, however, did not hold up on longer follow-up.

The larger, more recent PEXIVAS trial then tested plasma exchange across a broader group of ANCA-vasculitis patients and found that it neither reduced the risk of end-stage kidney disease nor clearly improved outcomes in pulmonary hemorrhage. But there are caveats: the trial did not require kidney biopsies for enrollment, making it hard to separate patients with early, recoverable kidney damage from those with advanced scarring. Some clinicians argue that a carefully selected subgroup, particularly those with very acute kidney failure and minimal chronic scarring, may still benefit.²¹ In practice, plasma exchange is now used selectively rather than routinely, reserved mainly for patients with life-threatening manifestations like severe alveolar hemorrhage or rapidly worsening kidney function that is not responding to standard drugs.

Prognosis and Long-Term Outlook

Before modern immunosuppressive treatments, GPA was almost universally fatal within a year. Today the picture is far better, though the disease remains serious. A study tracking patients from diagnosis reported survival rates of about 78% at one year, 71% at three years, 63% at five years, and 55% at ten years. The risk was steepest in the first six months, when the hazard of death was over twenty times higher than in a matched comparison group. After the first year, that excess risk dropped substantially.⁹

When deaths do occur, the leading cause is cardiovascular disease, accounting for about 38% of deaths in one cohort, followed by active vasculitis itself at roughly 33% and infections at about 22%.²² The high rate of cardiovascular death reflects both the vascular damage from the disease itself and the metabolic side effects of long-term steroid and immunosuppressive use. Infection risk is a constant concern, since the very drugs that control GPA also suppress the immune system’s ability to fight off bacteria, viruses, and fungi.

GPA in Children

Childhood-onset GPA is uncommon but presents with some notable differences from the adult disease. Alveolar hemorrhage and lung nodules are especially prominent in children, occurring in over 60% of pediatric cases. Saddle nose deformity and subglottic stenosis, while present in adults, develop in roughly 10% of children with GPA, making them complications clinicians watch for closely in younger patients.²³ There is also a sex difference: about 70% of childhood-onset cases occur in girls, whereas in adults the disease is more evenly distributed or slightly more common in men.

One practical frustration is that no separate pediatric treatment guidelines exist. Children with GPA are managed according to adult protocols, with doses adjusted for weight. The lower rate of c-ANCA positivity in children compared to adults can slow diagnosis, since the classic antibody marker is less reliably present.²⁴

Fatigue and Quality of Life

Even when the disease is technically in remission and blood markers look normal, many patients with GPA deal with a burden that does not show up on lab results. Fatigue is the single biggest quality-of-life complaint. In a study comparing patients who had ANCA-associated vasculitis with population controls, people with the disease were more than twice as likely to report moderate or severe fatigue. They were also about two and a half times more likely to report impaired physical health.²⁵ Interestingly, rates of clinical depression and psychological distress in that study were no higher than in the general population, suggesting the fatigue is not simply a manifestation of mood disorder.

Other research has found that depression, anxiety, and sleep disturbances, when they do occur in GPA patients, have an outsized impact on quality of life even if their severity is mild to moderate.²⁶ Fatigue in particular tends to be underaddressed in clinic visits that focus on organ damage and ANCA titers, leaving patients feeling that the thing affecting them most on a daily basis is the thing their doctors discuss least. Raising this with your treatment team is worthwhile, since some causes of fatigue, like anemia, thyroid dysfunction, or medication side effects, are treatable once identified.